Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Weekly Decitabine/Venetoclax in MDS and AML
NCT05184842Phase 2Recruiting
- Sponsor
- Montefiore Medical Center
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine and venetoclax in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), sponsored by Montefiore Medical Center. Primary endpoint: Percentage of Participants Who Are Able to Continue on Treatment Without Dose Interruptions or Delays at 12 weeks. Started Mar 2022; status: recruiting.
02
Drugs
decitabinevenetoclax
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05184842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184842.